CPT code 83937 represents a laboratory assay that quantifies osteocalcin (bone Gla protein, BGP) in serum or plasma to evaluate bone formation and monitor response to bone-building therapies. Nationally, this code is relevant for clinicians managing metabolic bone disease, endocrinologists, rheumatologists, and laboratories that provide specialty bone turnover testing. The test contributes clinical information about bone turnover dynamics and can influence treatment decisions in osteoporosis and other bone disorders.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical context for ordering the test, typical sites of service and service type, and a concise summary of billing considerations tied to this laboratory procedure. The publication provides benchmarks and policy-related context where available, outlines common billing modifiers, and clarifies typical clinical indications for the assay. This summary is intended for a national audience of laboratory administrators, billing professionals, and clinicians who require a clear, concise reference for CPT code 83937 and its role in bone metabolism testing.